- Home
- ROIV vs XYL Comparison
ROIV vs XYL Comparison
Compare ROIV & XYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | XYL |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2B | 26.0B |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ROIV | XYL |
|---|---|---|
| Price | $35.01 | $119.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | $28.94 | ★ $152.50 |
| AVG Volume (30 Days) | ★ 5.0M | 1.8M |
| Earning Date | 05-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.49% |
| EPS Growth | N/A | ★ 7.40 |
| EPS | N/A | ★ 0.79 |
| Revenue | $8,260,000.00 | ★ $9,035,000,000.00 |
| Revenue This Year | N/A | $2.79 |
| Revenue Next Year | $744.61 | $4.49 |
| P/E Ratio | ★ N/A | $147.94 |
| Revenue Growth | N/A | ★ 5.52 |
| 52 Week Low | $10.90 | $105.29 |
| 52 Week High | $37.00 | $154.27 |
Technical Indicators
Market Signals| Indicator | ROIV | XYL |
|---|---|---|
| Relative Strength Index (RSI) | 57.78 | 54.07 |
| Support Level | $33.56 | $115.88 |
| Resistance Level | $37.00 | $120.49 |
| Average True Range (ATR) | 1.11 | 2.72 |
| MACD | -0.24 | -0.59 |
| Stochastic Oscillator | 41.02 | 37.41 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About XYL Xylem Inc. New
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $9 billion in revenue in 2025.